Other key analyst calls in the stocks under $10 have been included below.
Himax Technologies, Inc. (NASDAQ: HIMX) was raised to Buy from Neutral at BofA Merrill Lynch on Tuesday. The price target was raised to $7.60 from $7.00 in the call. Earnings drove this stock higher later in the week, up to $7.25 at one point on Friday. What we would point out here is that Himax shares were at $6.41 prior to the upgrade — and Merrill Lynch even lowered earnings estimates, but said the core business is in recovery.
inContact, Inc. (NASDAQ: SAAS) received an upgrade from Oppenheimer on Thursday. The firm raised its rating to Outperform from Perform and the price target was set at $12. Shares had been at $7.68 at the prior close, but the company handily beat earnings. In fact, it closed at $9.00 on that day, and shares were up at $9.08 late in Friday’s trading session.
La Jolla Pharmaceutical Co. (NASDAQ: LJPC) is only about two weeks past a share sale, yet this last Monday brought a new call where it was started with a Buy rating at Jefferies. Shares were at $9.40 before the call, and rose to $9.85 after the call. Then shares went to a close of $10.06, but drifted lower on Wednesday and Thursday. By Friday’s trading session the stock was up over 25 at $10.20 in mid-day trading. We will leave this one up to you to decide based upon that $10 threshold violation, but this stock has literally gone all over the place in 2014.
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) was recently featured in our own 4 Biotech Analyst Picks With 100% Upside (or More!) based upon multiple analyst views. The top bill here is the pancreatic cancer targeting. Some of the calls may not be breaking calls, but here were some of the targets cited: Brean says Buy with a $16 target; Guggenheim says Buy with a $15 target; and J.P. Morgan says Buy with a $14 target – and the consensus price target is $13.25. We had also previously disclosed that Merrimack had seen key insider buying of late.
Mueller Water Products, Inc. (NYSE: MWA) was raised on Tuesday to Buy from Hold at Brean Capital after the water infrastructure player showed improved quarterly earnings. Shares had been at $7.81 prior to the news, but the stock was up at $8.59 in Friday afternoon trading. Brean’s $10 target is even short of the $10.46 consensus price target.
POZEN Inc. (NASDAQ: POZN) was raised to Buy from Hold at Ascendiant Capital Markets on Friday morning. This pain related biotech outfit was raised after beating earnings expectations with actual earnings on Thursday. This upgrade had POZEN’s stock up over 7% at $8.05 late in Friday’s trading session.
Sypris Solutions Inc. (NASDAQ: SYPR) was raised to Buy from Hold at Needham & Co. on Wednesday. This upgrade was after earnings, and the firm assigned a $6 target. That was versus a $3.91 prior close — indicating 50% upside before the call — but Sypris shares were up at $4.30 in Friday’s trading session.
In case you did not see Friday’s top analyst upgrades and downgrades, they included shares of Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and more.